Introduction Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), including administration of booster doses, continues to be the most effective method …

Introduction Immunocompromised individuals have been shown to mount a reduced
response to vaccination, resulting in reduced vaccine effectiveness in this cohort. Therefore …

Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Objective To compare the efficacy of covid-19 vaccines between immunocompromised and
immunocompetent people. Design Systematic review and meta-analysis. Data sources …

Background: Even 3 years into the COVID-19 pandemic, questions remain about how to
safely and effectively vaccinate vulnerable populations. A systematic analysis of the safety …

Background High efficacy in terms of protection from severe COVID‐19 has been
demonstrated for several SARS‐CoV‐2 vaccines. However, patients with compromised …

Several population groups display an increased risk of severe disease and mortality
following SARS-CoV-2 infection. These include those who are immunocompromised (IC) …

The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …

Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

Background Inactivated, whole-virion vaccines have been used extensively in the SARS-
CoV-2 pandemic. Its efficacy and effectiveness across regions have not been systematically …